



**INFORMATION  
DISCLOSURE  
STATEMENT**

Application #	10/560,348
Confirmation #	6403
Filing Date	June 11, 2004
First Inventor	WORSLEY, Andrew Peter
Art Unit	
Examiner	
Docket #	P08804US00/RFH

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

S I R :

**This IDS is submitted pursuant to 37 CFR. §1.97-1.98 and includes the following:**


- ☒ A **listing** of the references on PTO-1449.
- ☒ A copy of all **non-US** references which are listed on the PTO-1449 (US refs not required).
- ☐ A copy of a corresponding foreign **Search Report** which explains the relevance of the references noted therein.
- ☐ A separate **explanation of relevance**.

**Please note the following particulars concerning the filing of this IDS:**

- ☒ 1. This IDS is filed at whichever is the latest of:
    - within three months of the filing date of a NATIONAL APPLICATION other than a CPA, or
    - within three months of the date of entry into the NATIONAL STAGE as set forth in 37 CFR. §1.491 in an international application, or
    - before the mailing date of a first Office Action on the merits or after filing of an RCE (*but if a first Office Action is mailed but not yet received and the date on the face of the attached foreign communication makes it evident that this IDS is submitted within three months from the mailing of the search report, then applicant is entitled to have this IDS considered under 2.B. below and such boxes should be considered as having been checked*).
  - ☐ 2. This IDS is filed **after a first Office Action**, but before a Final Action, Allowance, or any other action which closes prosecution, **and**:
    - ☐ A. Is accompanied by a payment in the amount of \$180.00 required by 37 CFR. §1.17(p).
- or
- ☐ B. I hereby state that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
  - ☐ C. I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.
  - ☐ D. An appropriate Statement is attached.

- ☐ 3. This IDS is filed **after** a final action or allowance, but on/before payment of the issue fee, and:
- ☐ A. is accompanied by a payment in the amount of \$180.00 required by 37 CFR. §1.17(p).
- and
- ☐ B. I hereby state that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
- ☐ C. I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.
- ☐ D. An appropriate Statement is attached.
- ☐ 4. This IDS does not comply with 37 CFR 1.97-1.98, and is being filed **for placement in the file** pursuant to 37 CFR. §1.97(i).
- ☐ 5. It will also be appreciated that:
- a. It is believed that this IDS complies fully with 37 CFR 1.56 and 1.97-98 and with MPEP § 609; but if for some reason it does not and will not be entered, the examiner is requested to telephone the undersigned so that any deficiency can be timely remedied.
- b. Some of the documents may have markings thereon, but no significance should be attached to those markings.
- c. These documents are not necessarily analogous art.
- d. Where an English language translation of an abstract is provided from a public source, applicant cannot vouch for the accuracy of that translation.
- ☒ 6. If no payment is enclosed and a fee is due in connection with this communication or if the payment enclosed is insufficient, the Director is authorized to charge any fee or additional fee due with this communication to Deposit Account No. 12-0555.


Respectfully submitted,



By: Ross F. Hunt, Jr.  
Registration No.: 24082

Date: March 18, 2007

**STITES & HARBISON PLLC** ♦ 1199 North Fairfax St. ♦ Suite 900 ♦ Alexandria, VA 22314  
TEL: 703-739-4900 ♦ FAX: 703-739-9577 ♦ CUSTOMER NO. 00881



Customized PTO/SB/08a+b (09-06)


<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application #	10/560,348
	Confirmation #	6403
	Filing Date	June 11, 2004
	First Inventor	WORSLEY, Andrew Peter
	Art Unit	
	Examiner	
Sheet 1 of 2	Docket #	P08804US00/RFH

**U.S. PATENT DOCUMENTS**

Exam. Initial*	Document No. Number - Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.
	US-3,981,863	09-21-1976	Niswender, et al.	
	US-4,377,595 A	03-22-1983	Wurtman	
	US-4,431,670 A	02-14-1984	Heller	
	US-4,652,559 A	03-24-1987	Szmuszkowicz	
	US-4,843,071 A	06-27-1989	Hohenwarter	
	US-4,880,833 A	01-14-1989	Knoll	
	US-5,039,668 A	08-13-1991	Colina	
	US-6,096,317 A	08-01-2000	Desantis, et al.	
	US-6,200,607	03-13-2001	Bridgeman	
	US-6,096,737 (Equiv. of WO 96/11009)	08-01-2000	Loder	
	US-6,423,349 (Equiv. of WO 01/26642 )	07-23-2002	Sherratt, et al.	
	US-2003/0148991 (Equiv. of WO 10/85165)	08-07-2003	Hahnlein	
	US-6,713,082 (Equiv. of EP 1112693	03-30-2004	Van Loon, et al.	
	US-2006/0252727 (Equiv. of WO 03/049687)	11-09-2006	Ehrenpreis, et al.	
	US-6,335,323 (Equiv. of WO 98/01157)	01-01-2002	Worsley	
	US-6,989,380 (Equiv. of WO 98/08520)	01-24-2006	Horrobin, et al.	
	US-5,189,064 (Equiv. of WO 89/03211)	02-23-1993	Blum, et al.	
	US-6,159,505 (Equiv. of WO 97/26897)	12-12-2000	Piper	
	US-6,441,038 B1	08-27-2002	Loder et al.	

**FOREIGN PATENT DOCUMENTS**

Exam. Initial*	Country-Number-Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.	Trans- lation
	WO 00/50028	08-31-2000	Worsley		
	WO 00/56404 A1	09-28-2000	Kilgowan Limited		



Submission for Form 1449/APTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application #	10/560,348
	Confirmation #	6403
	Filing Date	June 11, 2004
	First Inventor	WORSLEY, Andrew Peter
	Art Unit	
	Examiner	
Sheet <u>2</u> of <u>2</u>	Docket #	P08804US00/RFH

NON PATENT LITERATURE DOCUMENTS		
Exam. Initial*	Include NAME of the author (in CAPS), Title of Article/Item, Date, Page(s), Volume-Issue No., Publisher, City and/or Country where published	Translation
	SENSBA, JUNICHI et al., "Evaluation of antidepressant properties of monoamine precursors by the forced-swimming test in mice," <i>Database Chemabs [online] Chemical Abstracts Service</i> , 1988, Vol. 8(1):87-88, Columbus, OH	
	BECKMAN, H. et al., "DL-Phenylalanine in depressed patients: An open study," <i>Journal of Neural Transmission</i> , 1977, ol. 41: 123-134; Springer Verlag, Vienna	
	BIOENERGENE, CO. LTD, <i>Database WPI</i> ; Section Ch, Week 200252, 2002, Derwent Publications Ltd., London, GB	
	PICKAR D et al, "Tyramine infusions in bi polar illness behavioral effects and longitudinal changes in pressor sensitivity," <i>American Journal of Psychiatry</i> , 1979, Vol. 136, No. 11:1460-1463.	
	OKADA S et al, "Effect of methylcobalamin on diminished motor nerve conduction velocity in the tibial nerve of poorly controlled diabetics," <i>Clinical Trials J</i> , 1985, 22(6): 534-536.	
	SIMON K.H., "Zur behandlung therapieresistenter schmerzzustande mit hydroxocobalamin" <i>Med.Mschr.</i> , 1974, 28/10 (466-468), Germany, West	
	CALANCA, A., "Hydroxytryptophane (oxitriptan) en association avec les antidepressseurs classiques: Une ulterieure possibilite therapeutique," <i>Schweiz. Rundsch. Med. Prax.</i> , 77/34; 1988, Switzerland	
	SEGAWA et al., "Effect of Lofepamine and other Antidepressants on the Uptake of 5 Hydroxytryptamine and Noradrenaline into Rat Brain Monoaminergic Neurons," <i>J. of Pharm. and Pharmac</i> , 1977, 29/3: 139-142. (abs.)	
	MAX, M. B. "Antidepressant Drugs as Treatments for Chronic Pain-Efficacy and Mechanisms," <i>Advances in Pain Research and Therapy</i> , 1995, Vol. 22:501-515; (abstract only).	
	KLINE et al., "A Pattern of Antidepressive Effect of Tryptophan and Imipramine in Males & Females," 1974, 35/10: 481-483 (abstract only).	
	FREEDMAN et al. "Vascular Headache: A Presenting Symptom of Multiple Sclerosis," <i>Canadian J. of Neurological Sciences</i> , 1989, Vol. 16, No. 1:63-66;	
	HOOGE et al., "Trigeminal Neuralgia in Multiple Sclerosis," <i>Neurology</i> , 1995, Vol. 45: 1294-1296	
	BRISMAN, RONALD, "Trigeminal Neuralgia in Multiple Sclerosis," <i>Arch. Neurol.</i> , 1987, Vol. 44:379-381.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* Examiner: Initial if considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.